Bicara Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Research and development | — | $63.6M | $30.6M | — |
| Operating expenses | $155.6M | $82.4M | $39.9M | — |
| Operating income | -$155.6M | -$82.4M | -$39.9M | — |
| Pretax income | -$137.7M | -$67.8M | -$52.0M | — |
| Income tax expense | $217,000 | $187,000 | $5,000 | — |
| Net income | -$137.9M | -$68.0M | -$52.0M | — |
| Balance Sheet | ||||
| Cash and equivalents | $96.7M | $489.7M | $230.4M | — |
| Current assets | $422.1M | $502.5M | $231.1M | — |
| Total assets | $431.0M | $510.0M | $234.0M | — |
| Current liabilities | $28.9M | $18.0M | $15.1M | — |
| Total liabilities | $29.5M | $18.1M | $15.5M | — |
| Stockholders' equity | $401.5M | $491.9M | -$148.8M | -$98.8M |
| Cash Flow Statement | ||||
| Cash from operations | -$106.8M | -$74.8M | -$45.6M | — |
| Depreciation and amortization | $105,000 | $56,000 | $19,000 | — |
| Stock-based compensation | $15.0M | $7.4M | $1.9M | — |
| Capital expenditure | $280,000 | $71,000 | $586,000 | — |
| Free cash flow | -$107.1M | -$74.8M | -$46.2M | — |
| Impairments | $0 | $0 | $0 | — |
Shares outstanding 65.7M · Free float 74.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.